3 results
To assess the rates of preliminary response and sustained remission of AASV following rituximab (on the basis of former studies, 86% sustained remission expected with rituximab compared to 75% in control group).To assess safety of a rituximab…
Primary objective: To evaluate the efficacy of IVIg treatment (4 courses of treatment, 3 weeks apart) compared to placebo on pain alleviation. Secondary objectives: 1. Pain intensity, pain qualities, and other SFN related complaints, daily and…
Objective: The primary objective is to assess the effects of continuous monitoring of patients in the acute admission ward (AAW) with a wearable sensor on the percentage of patients who can be discharged home. Secondary objectives are to assess the…